CRISPR is an exploratory strategy with potential for treatment of RNA-triggered diseases. Will DNA or RNA targeting prove to be the best approach for DM?
Genetic and epigenetic mechanisms drive differences between CDM and DM1—a new study elucidates downstream signaling pathways that underlie their diverse phenotypes and represent putative therapy development targets for CDM.
Age and gender impact the onset and progression of DM2, but the pattern shows both similarities and differences from that of DM1.
Judy Marks remembers getting sick at age 32 and feeling like it was the worst flu she ever had, only it didn’t go away. Her doctor dismissed it at first as being all in her head. Her sister thought she was faking it to get attention. Her mother-in-law said she was “lazy.”
MDF included a number of authors and artists at the 2017 MDF Annual Conference. Learn more, in these artists' words, about some of their creative efforts and how to access their publications and artwork.